Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Galderma’s New IL‑17A & SIRT1 Drugs Show Early Promise Despite Market Slump

Galderma’s early‑stage IL‑17A and SIRT1 drugs show promise, but investors stay cautious as the Swiss market weighs regulatory milestones and pipeline risk.

Dr. Michael Chen

10/11/2026, 22:00

5 minutes to read

Johnson & Johnson Accelerates Innovation: FDA Approval, Psychedelic Investment & Psoriasis Breakthroughs

Johnson & Johnson’s latest breakthroughs: accelerated HNSCC approval, $100M psychedelic investment, and Phase 3 success in PsA – redefining oncology, mental health, and rheumatology.

Dr. Michael Chen

10/11/2026, 10:54

5 minutes to read

Alnylam’s Dual‑Mechanism Therapy Hits Key Milestones, Poised to Transform Chronic Hepatitis Delta Treatment

Alnylam’s dual‑mechanism therapy for chronic hepatitis delta hits key virologic milestones, offering durable viral suppression and improved liver health with a single monthly injection—transformative potential for an orphan disease.

Dr. Michael Chen

09/11/2026, 21:35

3 minutes to read

J&J’s Phase 2 Nipocalimab Boosts Salivary Flow, Phase 3 ICOTYDE Meets Primary Endpoint in Psoriatic Arthritis

Johnson & Johnson’s new nipocalimab and ICOTYDE therapies show breakthrough efficacy in Sjögren’s syndrome and psoriatic arthritis, with significant symptom relief and a favorable safety profile.

Dr. Michael Chen

08/11/2026, 18:10

4 minutes to read

Johnson & Johnson Accelerated Approval of Rybrevant Faspro for Advanced Head‑and‑Neck Cancer

Johnson & Johnson secures FDA approval for Rybrevant Faspro, a dual‑targeted antibody‑drug conjugate that offers subcutaneous treatment for advanced head‑and‑neck cancer, blending direct cytotoxicity with immune checkpoint inhibition.

Dr. Michael Chen

07/11/2026, 22:13

4 minutes to read

Fidelity’s 5.6% Danaher Stake: What the 13‑G Filing Means for Investors

Danaher Corp. discloses FMR LLC’s 5.6% passive stake via a Schedule 13G filing—no influence on management, just a regulatory update for investors.

Dr. Michael Chen

07/11/2026, 21:22

One minute to read

Danaher Corp: FMR LLC & Abigail Johnson Acquire 5.6% Passive Stake, Files SEC 13G

FMR LLC and Abigail P. Johnson now own ~5.6% of Danaher Corp. Their passive 13G filing confirms no control intent, boosting investor confidence while keeping Danaher’s operations unchanged.

Dr. Michael Chen

06/11/2026, 22:07

3 minutes to read

Teva Files Q3 2026 10‑Q, Confirms Full SEC Compliance and Operational Stability

Teva’s Q3 2026 10‑Q confirms full SEC compliance, steady operations, and no new therapeutic updates—an essential check-in for investors.

Dr. Michael Chen

06/11/2026, 16:33

3 minutes to read

Amgen Q3 Earnings Beat Estimates, Raises 2025 Revenue & EPS Forecasts

Amgen tops Q3 earnings with $10.3 bn revenue, beating estimates, and raises 2025 outlook amid strong Repatha, Prolia and new Voxzogo launch.

Dr. Michael Chen

06/11/2026, 12:02

4 minutes to read

United Therapeutics Q3 2026: Revenue Grows 4% as Pulmonary Therapies Expand

United Therapeutics reports a 4 % revenue rise in Q3 2026 driven by FDA‑approved pulmonary hypertension therapy SGC‑X and expanding oxygen‑carrier pipeline, highlighting steady growth amid investment‑heavy earnings.

Dr. Michael Chen

06/11/2026, 03:15

3 minutes to read

Newer articles Older articles